These results demonstrated that 2-APQC can improve ISO-induced HF, myocardial hypertrophy and abnormal myocardial fibrosis by activating SIRT3 and suppressing the AKT/mTOR/p70S6K and TGF-β/Smad3 pathways. Here, AKT1 is linked to cardiac hypertrophy.